Description Proper Usage Precautions Possible Side effects
ChemicalBook > CAS DataBase List > Solifenacin succinate

Solifenacin succinate

Description Proper Usage Precautions Possible Side effects
Product Name
Solifenacin succinate
CAS No.
242478-38-2
Chemical Name
Solifenacin succinate
Synonyms
CS-353;Vesikur;vesicare;YM 67905;Solfenacin;42478-38-2;IsoprenalinoeSulfate;solifenacin succinate;Solefinacin Succinate;Sophenazine succinate
CBNumber
CB3500859
Molecular Formula
C27H32N2O6
Formula Weight
480.56
MOL File
242478-38-2.mol
More
Less

Solifenacin succinate Property

Melting point:
~145°
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
Methanol (Slightly, Heated, Sonicated), Water (Slightly, Sonicated)
form 
Solid
color 
White to Off-White
Merck 
14,8712
Stability:
Hygroscopic
CAS DataBase Reference
242478-38-2(CAS DataBase Reference)
More
Less

Safety

RTECS 
NW7136000
HS Code 
29339900
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

TCI Chemical
Product number
S0944
Product name
Solifenacin Succinate
Purity
>98.0%(HPLC)
Packaging
25mg
Price
$63
Updated
2024/03/01
TCI Chemical
Product number
S0944
Product name
Solifenacin Succinate
Purity
>98.0%(HPLC)
Packaging
100mg
Price
$161
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
10mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
25mg
Price
$48
Updated
2024/03/01
Cayman Chemical
Product number
17320
Product name
Solifenacin (succinate)
Purity
≥98%
Packaging
50mg
Price
$86
Updated
2024/03/01
More
Less

Solifenacin succinate Chemical Properties,Usage,Production

Description

Solifenacin succinate is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence.

Proper Usage

  1. This medication should be taken with liquids and swallowed whole. It may be taken with or without food.
  2. Take only the amount of this medication that has been prescribed for you by your doctor; taking more than the prescribed amount can cause adverse effects.
  3. If you miss a dose of this medication, begin taking it again the next day. Do not take two doses of solifenacin succinate in the same day.

Precautions

  1. Individuals with any of the following medical problems should not take this medication: urinary retention, gastric retention, narrow angle or uncontrolled glaucoma, or severe kidney problems. Solifenacin succinate can aggravate each of these conditions.
  2. Solifenacin succinate may cause blurred vision; do not engage in potentially dangerous activities such as driving until you know the effect of the medication on your vision.
  3. This medication, like all anticholinergic medications, may cause drying of the mouth. Since continued dryness of the mouth can increase the risk of dental disease, alert your dentist if you are taking this medication.
  4. Like all anticholinergic medications, solifenacin succinate can cause or worsen constipation.
  5. Because of decreased sweating, this medication can cause heat prostration when used in a very hot environment.
  6. This medication has not been studied in pregnant women. However, it has been shown in animal studies to impact preand postnatal development. If you are pregnant, or planning to become pregnant, do not start this medication before you have discussed it with your physician.
  7. It is not known whether solifenacin succinate passes into breast milk. Women who taking this medication and wish to breastfeed should discuss it with their physician.

Possible Side effects

  1. Side effects that are expected with this type of medication and do not require medical attention unless they continue or are bothersome: dry mouth; dry eyes; constipation, blurred vision, difficult urination.
  2. Less common side effect that should be reported to your physician: severe abdominal pain.
  3. Symptoms of overdose: severe central anticholinergic effects, including blurred vision; clumsiness or unsteadiness; confusion; seizures; severe diarrhea; excessive watering of the mouth; increasing 240 Multiple Sclerosis: A Self-Care Guide to Wellness muscle weakness (especially in the arms, neck, shoulders, and tongue); muscle cramps or twitching; severe nausea or vomiting; shortness of breath; slow heartbeat; slurred speech; unusual irritability, nervousness, or restlessness; unusual tiredness or weakness.

Description

Solifenacin is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification. The pooled results of four phase III trials concluded that 63% of women receiving 5mg of solifenacin once daily and 68% of women receiving 10mg once daily reported a 50% or more reduction in urgency episodes, compared to 44% of women taking placebo. This compares with a 53% reduction in patients receiving tolterodine twice daily. In another placebo-controlled trial, with the change in the number of micturitions in a 24-h period as the primary endpoint, once-daily solifenacin recorded an 18% decrease for a 5-mg dose and a 21% decrease for a 10-mg dose compared to 10% with placebo. Pharmacokinetic studies have demonstrated that solifenacin has an oral bioavailability of 90%, a long elimination half-life (50 h), low clearance (9.39 L/h), a mean Vss of 599 L, a Cmax of approximately 14 ng/mL, and a time to maximal plasma concentration of 4 h making it suitable for q.d. dosing. Furthermore, these PK parameters are not affected by food ingestion. Solifenacin is excreted predominantly in the feces with only 3–6% found in urine. It is contraindicated in patients with hepatic impairment, gastric retention, urinary retention, or uncontrolled narrow angle glaucoma. Further precautions, such as dose adjustment, should be considered for patients with concurrent use of ketoconazole or other potent CYP3A4 inhibitors or for patients with a history of QT prolongation or currently on medications known to prolong the QT interval. Finally, while other muscarinic antagonists have been explored in the treatment of irritable bowel syndrome (IBS), it is too early to predict the therapeutic utility of solifenacin for IBS although animal studies are promising.

Chemical Properties

White Solid

Originator

Yamanouchi (Japan)

Uses

Muscarinic M3 receptor antagoinst. Used in treatment of urinary incontinence.

Uses

sedative

Uses

Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

Definition

ChEBI: Solifenacin succinate is a member of isoquinolines.

brand name

Vesicare (Astellas).

General Description

Solifenacin succinate (Vesicare),(+)-(1S, 3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, is a competative antagonistfor M1, M2, and M3 receptor subtypes. One of the issues surroundingthe use of such antagonists is the selectivity for thebladder over other tissue such as the salivary glands. It isreported that the selectivity of solifenacin for bladder muscarinicreceptors over salivary receptors is superior to theeffects observed with oxybutynin.

Clinical Use

Selective M3 antimuscarinic
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency

in vitro

in radioligand receptor binding assay, the kivalues of solifenacin for human muscarinic m1, m2, m3, m4and m5receptors were 26, 170, 12, 110 and 31 nm, respectively. in isolated rat urinary bladder, solifenacin competitively antagonized carbachol-induced contractions, with a pa2value of 7.44±0.09[3].in bladder smooth muscle cells and salivary gland cells isolated from rats, solifenacin and the other antimuscarinic drugs inhibited carbachol-induced increases in intracellular ca2+levels in a concentration-dependent manner. thepki was 8.12for bladder smooth muscle cells, 3.6-fold more potent than that for salivary gland cells (pki=7.57) [1].

in vivo

in anesthetized rats, solifenacin dose-dependently inhibited carbachol-induced intravesical pressure elevation and salivary secretion, and exhibited selectivity (3.7- to 6.5-fold) for urinary bladder over salivary gland [1]. in anesthetized rats, solifenacin and oxybutynin increased the maximum bladder capacity in a dose-dependent manner and also decreased the maximum intravesical pressure [3].in healthy young men, multidose study evaluated doses. in the single-dose of solifenacin succinate (5-, 10-, 20-, and 30-mg), mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively.in the multidose study, the ranges were 2.9 to 5.8 and 45.0 to 64.8, respectively. the single-dose administration was well tolerated. the common adverse events were dry mouth, blurred vision, and headache [4].

Drug interactions

Potentially hazardous interactions with other drugs
Avoid if GFR<30 mL/min if also taking itraconazole, ketoconazole or ritonavir.
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

Metabolism

Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4 and is excreted mainly as metabolites in urine and faeces.

References

[1]. ohtake a, ukai m, hatanaka t, et al. in vitro and in vivo tissue selectivity profile of solifenacin succinate (ym905) for urinary bladder over salivary gland in rats[j]. european journal of pharmacology, 2004, 492(2): 243-250.
[2]. yang j, williams j a, yule d i, et al. mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization[j]. molecular pharmacology, 1995, 48(3): 477-485.
[3]. ohtake a, saitoh c, yuyama h, et al. pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents[j]. biological and pharmaceutical bulletin, 2007, 30(1): 54-58.
[4]. smulders r a, krauwinkel w j, swart p j, et al. pharmacokinetics and safety of solifenacin succinate in healthy young men[j]. the journal of clinical pharmacology, 2004, 44(9): 1023-1033.
[5]. cardozo l, lisec m, millard r, et al. randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder[j]. the journal of urology, 2004, 172(5): 1919-1924.

Solifenacin succinate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Solifenacin succinate Suppliers

Canada 3 China 363 Czech Republic 1 Europe 1 France 3 Germany 3 Greece 1 India 103 Israel 2 Italy 2 Japan 2 Malaysia 1 Malta 1 Mexico 2 Nepal 1 Philippines 1 Poland 1 South Korea 6 Spain 6 United Arab Emirates 1 United Kingdom 4 United States 34 Global 542
TCI Chemicals (India) Pvt. Ltd.
Tel
--
Fax
--
Email
sales-in@tcichemicals.com
Country
India
ProdList
6768
Advantage
58
VIVAN Life Sciences Pvt. Limited.
Tel
--
Fax
--
Email
info@vivanls.com
Country
India
ProdList
138
Advantage
50
SGMR Pharmaceuiticals Pvt Ltd
Tel
--
Fax
--
Email
api.marketing@sgmrpharma.com
Country
India
ProdList
51
Advantage
58
Saptagir Laboratories PVT.LTD.
Tel
--
Fax
--
Email
info@saptagirlabs.com
Country
India
ProdList
12
Advantage
58
VIJAYASAI LIFE SCIENCES PVT LTD
Tel
--
Fax
--
Email
info@vijayasai.co.in
Country
India
ProdList
13
Advantage
58
Jigs Chemical Limited
Tel
--
Fax
--
Email
info@jigschemical.com
Country
India
ProdList
235
Advantage
58
Manus Aktteva Biopharma LLP
Tel
--
Fax
--
Email
products@manusakttevabiopharma.in
Country
India
ProdList
275
Advantage
58
Hemen Life Sciences Private Limited
Tel
--
Fax
--
Email
info@hemenlifesciences.com
Country
India
ProdList
55
Advantage
58
SMS PHARMACEUTICALS LTD
Tel
--
Fax
--
Email
info@smspharma.com
Country
India
ProdList
30
Advantage
58
Pharma Affiliates
Tel
--
Fax
--
Email
@pharmaffiliates.com
Country
India
ProdList
6754
Advantage
58
Ralington Pharma
Tel
--
Fax
--
Email
info@ralingtonpharma.com
Country
India
ProdList
312
Advantage
58
Oceanic Pharmachem Pvt., Ltd. (OPPL)
Tel
--
Fax
--
Email
info@oceanicpharmachem.com
Country
India
ProdList
946
Advantage
58
Excel Industries Limited
Tel
--
Fax
--
Country
India
ProdList
18
Advantage
58
Nivon Specialties (India)
Tel
--
Fax
--
Email
info@nivonindia.com
Country
India
ProdList
154
Advantage
58
BDR Pharmaceuticals International Pvt., Ltd.
Tel
--
Fax
--
Email
marketing@bdrpharma.com
Country
India
ProdList
91
Advantage
58
Vivimed Labs Ltd.
Tel
--
Fax
--
Email
info@vivimedlabs.com
Country
India
ProdList
32
Advantage
58
Hetero Drugs Limited
Tel
--
Fax
--
Country
India
ProdList
174
Advantage
58
AMOLI ORGANICS PRIVATE LTD
Tel
--
Fax
--
Email
info@amoliindia.com
Country
India
ProdList
24
Advantage
58
Clearsynth Labs
Tel
--
Fax
--
Email
fo@clearsynth.com
Country
India
ProdList
3887
Advantage
58
Dazzle Corporation
Tel
--
Fax
--
Email
enquiry@dazzlecorporation.co.in
Country
India
ProdList
209
Advantage
58
Novas International
Tel
--
Fax
--
Email
info@novasinternational.com
Country
India
ProdList
210
Advantage
58
Sai Prathyu Marketing
Tel
--
Fax
--
Country
India
ProdList
162
Advantage
58
Orbit Lifescience Pvt., Ltd.
Tel
--
Fax
--
Email
orbit@orbitlifescience.com
Country
India
ProdList
206
Advantage
58
ENALTEC LABS PRIVATE LTD
Tel
--
Fax
--
Email
info@enaltec.com
Country
India
ProdList
27
Advantage
58
Unichem Laboratories Ltd.
Tel
--
Fax
--
Email
pankaj.manjrekar@unichemlabs.com
Country
India
ProdList
35
Advantage
58
Dharmanandan Export Pvt., Ltd.
Tel
--
Fax
--
Email
info@dnexport.com
Country
India
ProdList
161
Advantage
58
Meenaakshi Molecules Pvt., Ltd.
Tel
--
Fax
--
Email
Info@meenaakshi.in
Country
India
ProdList
32
Advantage
58
Glenmark Pharmaceuticals Limited
Tel
--
Fax
--
Email
GlobalPV@glenmarkpharma.com
Country
India
ProdList
37
Advantage
58
Sudarshan Group
Tel
--
Fax
--
Email
vijaya@sudarshangrp.com
Country
India
ProdList
40
Advantage
58
Goalsy Laboratories
Tel
--
Fax
--
Email
info@goalsylaboratories.com
Country
India
ProdList
42
Advantage
58
Unimark Remedies Ltd.
Tel
--
Fax
--
Email
sapnasingh@unimarkremedies.com
Country
India
ProdList
26
Advantage
58
Archerchem Healthcare Pvt., Ltd. (part of Archerchem Group)
Tel
--
Fax
--
Email
mayur@archerchem.com
Country
India
ProdList
147
Advantage
58
Sudarshan Pharma Industries Limited.
Tel
--
Fax
--
Email
@sudarshangrp.com
Country
India
ProdList
157
Advantage
58
Globofarm International Private Limited
Tel
--
Fax
--
Email
procurement@globofarm.net
Country
India
ProdList
188
Advantage
58
Amtec Health Care Private Limited
Tel
--
Fax
--
Email
nfo@amtechealthcare.com
Country
India
ProdList
21
Advantage
58
Ayon PharmaChem
Tel
--
Fax
--
Email
bhargav@ayonpharmachem.com
Country
India
ProdList
303
Advantage
58
Rivashaa Agrotech Biopharma Pvt. Ltd.
Tel
--
Fax
--
Email
source@rivashaa.com
Country
India
ProdList
986
Advantage
58
Sun Pharmaceutical Industries Ltd.
Tel
--
Fax
--
Email
SunPharma.IndiaBusiness@sunpharma.com
Country
India
ProdList
99
Advantage
58
Global Chem Asia Pacific
Tel
--
Fax
--
Email
ghu@globalchem.in
Country
India
ProdList
255
Advantage
58
Synthink Research Chemicals
Tel
--
Fax
--
Country
India
ProdList
398
Advantage
58
Pharma Links
Tel
--
Fax
--
Email
info@pharmalinksindia.com
Country
India
ProdList
85
Advantage
58
February Pharma
Tel
--
Fax
--
Country
India
ProdList
27
Advantage
58
Tyche Industries Limited
Tel
--
Fax
--
Country
India
ProdList
27
Advantage
58
AUROBINDO PHARMA LIMITED
Tel
--
Fax
--
Email
info@aurobindo.com
Country
India
ProdList
144
Advantage
58
MEGAFINE PHARMA (P) LIMITED
Tel
--
Fax
--
Email
info@megafine.in
Country
India
ProdList
26
Advantage
58
ALEMBIC PHARMACEUTICALS LIMITED
Tel
--
Fax
--
Email
infoal@alembic.co.in
Country
India
ProdList
62
Advantage
58
SynZeal Research Pvt Ltd
Tel
--
Fax
--
Email
standards@synzeal.com
Country
India
ProdList
6514
Advantage
58
Chemsynth Drugs & Pharmaceuticals Pvt Ltd.
Tel
--
Fax
--
Email
info@cdppl.com
Country
India
ProdList
71
Advantage
58
Molkem Chemicals Pvt. Ltd.
Tel
--
Fax
--
Email
hello@molkem.com
Country
India
ProdList
199
Advantage
58
Refsyn Biosciences Pvt., Ltd.
Tel
--
Fax
--
Email
info@refsynbio.com
Country
India
ProdList
226
Advantage
58
More
Less

View Lastest Price from Solifenacin succinate manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Solifenacin succinate 242478-38-2
Price
US $0.00/KG
Min. Order
1KG
Purity
99.0
Supply Ability
10KG/month
Release date
2021-07-03
Sinoway Industrial co., ltd.
Product
Solifenacin Succinate 242478-38-2
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
99% up, High Density
Supply Ability
20 tons
Release date
2022-07-19
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Solifenacin Succinate 242478-38-2
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-09-29

242478-38-2, Solifenacin succinateRelated Search:

Metroprolol succinate PHENYL VALERATE Fexofenadine Solifenacin Diethyl succinosuccinate Isoquinoline Succinic acid iron succinate Acetonylsuccinic acid diethyl ester Fexofenadine hydrochloride Sumatriptan Succimer Dimethyl succinate Disodium succinate 6alpha-Methylprednisolone sodium succinate SOLIFENACIN PHENYL RESIN Solifenacin Related Compound 18

  • VESICARE; YM905; YM-905; YM 905
  • CS-353
  • Solifenacin for System Suitability
  • 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate butanedioic acid
  • vesicare
  • solifenacin succinate
  • IsoprenalinoeSulfate
  • Solefinacin Succinate
  • Butanedioic acid, compd. with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
  • (1R,3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
  • (1S)-(3R)-1-Azabicyclo[2.2.2]oct-3-yl 3,4-Dihydro-1-phenyl-2(1H)- isoquinolinecarboxylate Butanedioic Acid
  • Vesikur
  • YM 67905
  • Solifenacin succinate(Vesicare)
  • Solifenacin Succinate API
  • Solifenacin succinate, >=98%
  • Solifenacin Succinate 1
  • Solfenacin
  • (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate monosuccinate
  • 3,4-Dihydro-1-phenyl-2(1H)- isoquinolinecarboxylate Butanedioic Acid
  • (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate monosuccinat
  • Solifenacin succinate, 98%, a muscarinic receptor antagonist
  • 1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 1-azabicyclo[2.2.2]octan-3-yl ester
  • 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid (Solifenacin?Succinate)
  • Solifenacin for system suitability CRS
  • Solifenacin succinate CRS
  • Solifenacin Succinate &gt
  • (S)-(R)-Quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate succinate
  • Solifenacin succinate USP/EP/BP
  • 42478-38-2
  • Solifenacin succinate (YM905)
  • Solifenacin for system suitability(Y0001743)
  • Solifenacin succinate (Y0001763)Q: What is Solifenacin succinate (Y0001763) Q: What is the CAS Number of Solifenacin succinate (Y0001763) Q: What are the applications of Solifenacin succinate (Y0001763)
  • Solifenacin Succinate (1615300)
  • Sophenazine succinate
  • Solifenacin Succinate EP
  • Solifenacin Succinate / (S,R)-Solifenacin Succinate
  • 242478-38-2
  • 2424-38-2
  • 24278-38-2
  • 42478-38-2
  • C23H26N2O2C4H6O4
  • C23H26N2OC4H6O4
  • Solifenacin
  • API